Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPENDIA Trial
2007-001394-29Phase 4Completed
- Sponsor
- Baxter
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of icodextrin, Nutrineal, calcium chloride and Physioneal in diabetes mellitus (DM) and end-stage kidney disease (ESKD) (2 arms), sponsored by Baxter. Primary endpoint: Change from baseline in HbA1c. Started Nov 2007; status: completed.
02
Drugs
icodextrinNutrinealcalcium chloridePhysioneal
03
Conditions
diabetes mellitus (DM)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2007-001394-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001394-29.